Literature DB >> 17644191

Overcoming penicillin failures in the treatment of Group A streptococcal pharyngo-tonsillitis.

Itzhak Brook1.   

Abstract

The causes of penicillin failure in eradicating Group A beta-hemolytic streptococcal pharyngo-tonsillitis (GABHS PT) are described. These include the presence of beta-lactamase producing bacteria that "protect" Group A beta-hemolytic streptococci (GABHS) from penicillins; the absence of bacteria that interfere with the growth of GABHS; co-aggregation between GABHS and Moraxella catarrhalis; and the poor penetration of penicillin into the tonsillar tissues and the tonsillo-pharyngeal cells. The use of antimicrobials that can overcome and modulate these phenomena and achieve better cure of the infection is described.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17644191     DOI: 10.1016/j.ijporl.2007.06.006

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  4 in total

1.  Reduced In Vitro Susceptibility of Streptococcus pyogenes to β-Lactam Antibiotics Associated with Mutations in the pbp2x Gene Is Geographically Widespread.

Authors:  James M Musser; Stephen B Beres; Luchang Zhu; Randall J Olsen; Jaana Vuopio; Hanne-Leena Hyyryläinen; Kirsi Gröndahl-Yli-Hannuksela; Karl G Kristinsson; Jessica Darenberg; Birgitta Henriques-Normark; Steen Hoffmann; Dominque A Caugant; Andrew J Smith; Diane S J Lindsay; David M Boragine; Timothy Palzkill
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

2.  StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice.

Authors:  Edilberto Postol; Raquel Alencar; Fabio T Higa; Samar Freschi de Barros; Lea M F Demarchi; Jorge Kalil; Luiza Guilherme
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

3.  In Vitro Antibacterial Activity of Essential Oils against Streptococcus pyogenes.

Authors:  Julien Sfeir; Corinne Lefrançois; Dominique Baudoux; Séverine Derbré; Patricia Licznar
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-11       Impact factor: 2.629

4.  Synergy and Mode of Action of Ceftazidime plus Quercetin or Luteolin on Streptococcus pyogenes.

Authors:  Supatcharee Siriwong; Kanjana Thumanu; Tanaporn Hengpratom; Griangsak Eumkeb
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-21       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.